Pfizer Ltd.
PFIZER · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹3,931.21.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%17.2%
- ✓Low debt (D/E < 0.5)0.02x
- ✓Positive free cash flow
- ✕Revenue growth > 10%6%
- ✕Earnings growing-40%
- ✓Net margin ≥ 10%28.7%
- ✓Current ratio > 1.56.06
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 19.18
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (28.7%).
- •Financially solid — Altman Z 19.18.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Trading in our value buy zone versus sector peers.
Threats
- •Earnings contracting year on year.
About Pfizer Ltd.
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.